XOMA
$23.22
Xoma
$.04
.17%
XOMA
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  ($0.27)
Revenue:  $3.24 Mil
Tuesday
Feb 4
8:20 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when XOMA reports earnings?
Beat
Meet
Miss

Where is XOMA's stock price going from here?
Up
Flat
Down
Stock chart of XOMA
Analysts
Summary of analysts' recommendations for XOMA
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1? with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California.
Peers
Regeneron PharmaceuticalsInterCeptVertex PharmaceuticalsBioMarin PharmaceuticalMylanZoetisJohnson & JohnsonUltragenyx PharmaceuticalBristol-Myers SquibbEndo International plc